All dressed up and know where to go: An example of how to use net benefit regression to do a cost-effectiveness analysis with person-level data (The 'A' in CEA)

Clinical Neuropsychiatry

Volumn 5, Issue 4, 2008, Pages 175-183

  Hoch, Jeffrey S ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Pharmacoeconomics Research Unit   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Phamacologic treatment; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MENTAL HEALTH CARE; PSYCHOTHERAPY; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 57749188663     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Devlin N, Parkin D (2004). Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econonomics 13, 5,437-452.
2. Doshi JA, Glick HA, Polsky D (2006). Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health 9, 34-340.
3. Drummond MF et al. (2005). Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, New York.
4. Evers SM, Van Wijk AS, Ament AJ (1997). Economic evaluation of mental health care interventions. A review. Health Economics 6, I61-I77.
5. Fenwick E, Marshall DA, Levy. AR, and Nichol G (2006). Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research 6, 52.
6. George B, Harris A, Mitchell A (2001). Cost effectiveness analysis and the consistency of decision making - evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmaco Economics 19, 11, 1103-1109.
7. Hoch JS, Dewa CS (2005). An introduction to economic evaluation: what's in a name? Canadian Journal of Psychiatry, 50, 159-166.
8. Hoch JS, Smith MW (2006). A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data. Journal of Trauma Stress 19, 787-797.
9. Hoch JS, Briggs AH, Willan AR (2002). Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econonomics 11, 415-430.
10. Hoch JS, Rock MA and Krahn A (2006). Using the net benefit regression framework to construct cost-effectiveness acceptability curves: An example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMCHealth Services Research 6, 68.
11. Polsky D, Doshi JA, Bauer MS, et al. (2006). Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 163, 2047-2056.
12. Williams A (1992). Cost-effectiveness analysis: Is it ethical? Journal of Medical Ethics 18, 7-11.